Investigator meeting · Dr. Oscar Petit

29 Aug 2026 · Phone · Dr. Oscar Petit, Ospedale San Raffaele · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0030—

Capture insight from this engagement

Location: Ospedale San Raffaele
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
Chemotherapy-free first line
Sequencing after progression

Scientific content used

PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Investigator meeting with oncology pharmacist at Ospedale San Raffaele. Discussed duration of response, chemotherapy-free first line, sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0030

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
10 Sept 2026, 11:43 UTC	Update	GNGrace Nakamura	status	Draft → Completed	—	UI